Bradley Neuenschwander, DO
Dermatology · Layton, UTNPI 1174740799
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 32.3% of the total. Reporting peaked in 2023 at $648 and has fallen 67.8% since, to $209 in 2025.
Across 167 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$898
- Novartis$600
- Johnson & Johnson$304
- LEO Pharma Inc.$136
- Pfizer$112
- Galderma Laboratories, L.p.$99
- plus $632 from 18 others
What the payments were for
- Food & beverage$2,51490%
- Education$26610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $898 |
| Novartis | 22 | $600 |
| Johnson & Johnson(2 entities) | 7 | $304 |
| LEO Pharma Inc. | 6 | $136 |
| Pfizer | 8 | $112 |
| Galderma Laboratories, L.p. | 6 | $99 |
| Biofrontera Inc. | 4 | $82 |
| Lilly USA, LLC | 4 | $75 |
| Sanofi | 4 | $65 |
| Abbott | 3 | $63 |
| Arcutis Biotherapeutics, Inc. | 3 | $52 |
| Strongbridge US Inc. | 2 | $43 |
| Amgen | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| UCB, Inc. | 1 | $30 |
| Incyte Corporation | 2 | $30 |
| Almirall LLC | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Dermira, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| GSK | 1 | $13 |
| Organon | 2 | $7 |
How this compares
$2,780 in reported general payments places this provider in the 65th percentile of 163 dermatology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 19 | $124,146 |
| Fluorouracil | 92 | $6,384 |
| Clobetasol Propionate | 43 | $2,094 |
| Ketoconazole | 63 | $1,265 |
| Metronidazole | 11 | $635 |
| Doxycycline Hyclate | 36 | $524 |
| Triamcinolone Acetonide | 43 | $488 |
| Spironolactone | 18 | $178 |
| Terbinafine Hcl | 12 | $112 |
| Finasteride | 14 | $56 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Layton
- Steven NickleLayton$11K
- Matthew InnesLayton$6K
- Jamison HarveyLayton$5K
- Michael MartineauLayton$3K
- Brayden ForbesLayton$2K
- Scott CheckettsLayton$2K
- Brian WilliamsMidvale$876K
- Travis JamesProvidence$437K
- Jason HadleyBountiful$294K
- Doug Lass ForshaWest Jordan$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.